Press Releases + New Year: - Any -2024202320222021202020192018201720162015201420132012201120102009 Items per page 102550 Date Title and Summary View Toggle SummaryNov 12, 2013 Galectin Therapeutics Reports Update on Enrollment of First Cohort of Phase 1 Clinical Trial and Third Quarter 2013 Financial Results View HTML Galectin Therapeutics Reports Update on Enrollment of First Cohort of Phase 1 Clinical Trial and Third Quarter 2013 Financial Results 23.3 KB Toggle SummaryOct 17, 2013 Galectin Therapeutics Announces Early Warrant Exercise by 10X Fund, Provides Update on Cash Position View HTML Galectin Therapeutics Announces Early Warrant Exercise by 10X Fund, Provides Update on Cash Position 14.5 KB Toggle SummaryOct 10, 2013 Galectin Therapeutics' Preclinical Data Published in PLOS ONE Show Its Galectin Inhibitors Reverse Cirrhosis and Significantly Reduce Fibrosis and Portal Hypertension Findings Suggest Role for GR-MD-02 and GM-CT-01 in Treatment of Liver Fibrosis and Cirrhosis in Humans View HTML Galectin Therapeutics' Preclinical Data Published in PLOS ONE Show Its Galectin Inhibitors Reverse Cirrhosis and Significantly Reduce Fibrosis and Portal Hypertension 18.2 KB Toggle SummarySep 23, 2013 Galectin Therapeutics Leadership to Present at Three Upcoming Conferences View HTML Galectin Therapeutics Leadership to Present at Three Upcoming Conferences 15.2 KB Toggle SummarySep 10, 2013 Galectin Therapeutics Receives US Patent for Potential Ground-Breaking Treatment for Fatty Liver Disease View HTML Galectin Therapeutics Receives US Patent for Potential Ground-Breaking Treatment for Fatty Liver Disease 18.3 KB Toggle SummaryAug 28, 2013 Galectin Therapeutics Announces Update on Warrant Exercises View HTML Galectin Therapeutics Announces Update on Warrant Exercises 15.6 KB Toggle SummaryAug 21, 2013 Galectin Therapeutics Announces $3 Million Private Placement of Restricted Stock View HTML Galectin Therapeutics Announces $3 Million Private Placement of Restricted Stock 15.9 KB Toggle SummaryAug 14, 2013 Galectin Therapeutics Reports Second Quarter 2013 Financial Results View HTML Galectin Therapeutics Reports Second Quarter 2013 Financial Results 18.1 KB Toggle SummaryAug 12, 2013 Galectin Therapeutics Receives FDA Fast Track Designation for GR-MD-02 for Fatty Liver Disease With Advanced Fibrosis View HTML Galectin Therapeutics Receives FDA Fast Track Designation for GR-MD-02 for Fatty Liver Disease With Advanced Fibrosis 18.1 KB Toggle SummaryAug 05, 2013 Reduction in Lung Fibrosis With the Anti-Galectin Drug GR-MD-02 Revealed in Preclinical Data Results Suggest Role for GR-MD-02 in Treating Idiopathic Pulmonary Fibrosis View HTML Reduction in Lung Fibrosis With the Anti-Galectin Drug GR-MD-02 Revealed in Preclinical Data 17.6 KB Pagination First page First Previous page Previous … Page 25 Current page 26 Page 27 Page 28 … Next page Next Last page Last
Galectin Therapeutics Reports Update on Enrollment of First Cohort of Phase 1 Clinical Trial and Third Quarter 2013 Financial Results 23.3 KB
Galectin Therapeutics Announces Early Warrant Exercise by 10X Fund, Provides Update on Cash Position 14.5 KB
Galectin Therapeutics' Preclinical Data Published in PLOS ONE Show Its Galectin Inhibitors Reverse Cirrhosis and Significantly Reduce Fibrosis and Portal Hypertension 18.2 KB
Galectin Therapeutics Receives US Patent for Potential Ground-Breaking Treatment for Fatty Liver Disease 18.3 KB
Galectin Therapeutics Receives FDA Fast Track Designation for GR-MD-02 for Fatty Liver Disease With Advanced Fibrosis 18.1 KB
